drugset / Trial / NCT05077800
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Phase 2
Active not recruiting
70 enrolled
Colin D. Weekes, M.D., PhD
Actuate Therapeutics Inc. · collabLustgarten Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease. The names of the study drugs involved in this study are: * 9-ING-41 * Losartan * Ferumoxytol * FOLFIRINOX (made up of 4 different drugs): * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin
Timeline
- Start
- 2022-03-21
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elraglusib | Small molecule | — | Intravenous |
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Subject | Leucovorin | Small molecule | — | Intravenous |
| Subject | Losartan | Other / unclassified | — | Oral |
| Subject | Oxaliplatin | Small molecule | — | Intravenous |
| Subject | fluorouracil | Small molecule | — | Intravenous |